Tumor Biology

, Volume 37, Issue 5, pp 5775–5779 | Cite as

RETRACTED ARTICLE: Downregulation of miR-185 and upregulation of miR-218 expression may be potential diagnostic and prognostic biomarkers of human chondrosarcoma

  • Peyman Karimi Goudarzi
  • Afshin Taheriazam
  • Saeid Asghari
  • Mohammad Jamshidi
  • Mohammadreza Shakeri
  • Emad Yahaghi
  • Alireza Mirghasemi
Original Article


Increasing evidence has confirmed that dysregulation of microRNAs (miRNAs) can contribute to the progression and metastasis of human tumors. Chondrosarcoma is the most common primary malignant bone tumor in adults and has no effective systemic treatment, and patients with this disease have poor survival. Thus, it is important to find new diagnostic markers and improve treatment options. In the current study, we are interested to examine the role of miR-185 and miR-218 expression in patients with chondrosarcoma using real-time PCR. Moreover, the association of the two miRNAs with clinicopathological features and prognosis was evaluated. Survival and Cox proportional hazards analyses were performed to find the association of miR-185 expression and miR-218 levels with prognosis in the patients. Our results indicated that the miR-185 expression was significantly downexpressed in clinical chondrosarcoma bone tissues compared with adjacent normal tissues (P = 0.001). MiR-218 expression level was increased in clinical chondrosarcoma bone tissue than those adjacent normal tissues (P = 0.001). Decreased expression of miR-185 showed remarkable correlation with advanced tumor stage (P = 0.019), tumor grade (P < 0.001), and distant metastasis (P = 0.001). Moreover, high expression of miR-218 was strongly correlated with advanced tumor stage (P = 0.014), tumor grade (P < 0.001), and distant metastasis (P = 0.002). Kaplan–Meier survival analysis revealed that the low miR-185 expression group and the high miR-218 expression group had remarkably shorter overall survival (log-rank test P = 0.007, P = 0.004). The multivariate Cox proportional hazards model indicated that decreased expression of miR-185 and increased expression of miR-218 (P = 0.017, P = 0.012), advanced tumor stage (P = 0.006, P = 0.012), tumor grade (P = 0.032, P = 0.016), and distant metastasis (P = 0.004, P = 0.015) were independently related to overall survival in patients with chondrosarcoma. In conclusion, downregulation of miR-185 and upregulation of miR-218 can be associated with progression of chondrosarcoma and also both of them may act as tumor suppressor genes in chondrosarcoma.


Chondrosarcoma PCR MicroRNAs Prognostic Pathology 


Conflicts of interest



  1. 1.
    Rozeman LB, Cleton-Jansen AM, Hogendoorn PC. Pathology of primary malignant bone and cartilage tumours. Int Orthop. 2006;30:437–44.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, Healey JH, et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res. 1998;16(5):585–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Erson AE, Petty EM. MicroRNAs in development and disease. Clin Genet. 2008;74(4):296–306.CrossRefPubMedGoogle Scholar
  5. 5.
    Liu W, Mao SY, Zhu WY. Impact of tiny miRNAs on cancers. World J Gastroenterol. 2007;13(4):497–502.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mutlu S, Mutlu H, Kirkbes S, Eroglu S, Kabukcuoglu YS, Kabukcuoglu F, et al. The expression of miR-181a-5p and miR-371b-5p in chondrosarcoma. Eur Rev Med Pharmacol Sci. 2015;19(13):2384–8.PubMedGoogle Scholar
  7. 7.
    Tsai CH, Tsai HC, Huang HN, Hung CH, Hsu CJ, Fong YC, et al. Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells. Oncotarget. 2015;6(1):258–70.PubMedGoogle Scholar
  8. 8.
    Liu GT, Huang YL, Tzeng HE, Tsai CH, Wang SW, Tang CH. CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. Cancer Lett. 2015;357(2):476–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010;402:135–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang X, Niey D, Caoj SH, Li Y. MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumor Biol. 2012;33:1589–97.CrossRefGoogle Scholar
  11. 11.
    Östling P, Leivonen SK, Aakula A. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011;71:1956–67.CrossRefPubMedGoogle Scholar
  12. 12.
    Xiang Y, Ma N, Wang D. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014;33:378–86.CrossRefPubMedGoogle Scholar
  13. 13.
    Fu P, Du F, Yao M, Lv K, Liu Y. MicroRNA-185 inhibits proliferation by targeting c-Met in human breast cancer cells. Exp Ther Med. 2014;8(6):1879–83.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One. 2010;5:e12560.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li J, Ping Z, Ning H. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012;13:16053–64.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tian H, Hou L, Xiong YM, Huang JX, She YJ, Bi XB, et al. MiR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep. 2015;33(2):981–9.PubMedGoogle Scholar
  17. 17.
    Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78.CrossRefPubMedGoogle Scholar
  18. 18.
    He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, et al. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2012;18:1491–8.PubMedCentralGoogle Scholar
  19. 19.
    Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A, et al. Change in expression of miRlet7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol. 2011;29:265–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao X, et al. Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2013;6(12):2904–11.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Peyman Karimi Goudarzi
    • 1
  • Afshin Taheriazam
    • 2
  • Saeid Asghari
    • 3
  • Mohammad Jamshidi
    • 4
    • 5
  • Mohammadreza Shakeri
    • 3
  • Emad Yahaghi
    • 6
  • Alireza Mirghasemi
    • 7
  1. 1.Department of NeurosurgeryAJA University of Medical SciencesTehranIran
  2. 2.Department of Orthopedics Surgery, Tehran Medical Sciences BranchIslamic Azad UniversityTehranIran
  3. 3.Department of Orthopaedic and Trauma SurgeryBirjand University of Medical SciencesBirjandIran
  4. 4.Cellular and Molecular Research CenterZahedan University of Medical SciencesZahedanIran
  5. 5.Department of Clinical Biochemistry, School of MedicineZahedan University of Medical SciencesZahedanIran
  6. 6.Department of Molecular BiologyBaqiyatallah University of Medical SciencesTehranIran
  7. 7.Department of OrthopedicsQom University of Medical SciencesQomIran

Personalised recommendations